EP0896622A4 - CHEMOKINE ALPHA 2 - Google Patents

CHEMOKINE ALPHA 2

Info

Publication number
EP0896622A4
EP0896622A4 EP97916062A EP97916062A EP0896622A4 EP 0896622 A4 EP0896622 A4 EP 0896622A4 EP 97916062 A EP97916062 A EP 97916062A EP 97916062 A EP97916062 A EP 97916062A EP 0896622 A4 EP0896622 A4 EP 0896622A4
Authority
EP
European Patent Office
Prior art keywords
disclosed
polypeptides
chemotactic cytokines
detecting
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97916062A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0896622A1 (en
Inventor
Jian Ni
Reiner L Gentz
Jeffrey Y Su
Haodong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP0896622A1 publication Critical patent/EP0896622A1/en
Publication of EP0896622A4 publication Critical patent/EP0896622A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
EP97916062A 1996-03-19 1997-03-19 CHEMOKINE ALPHA 2 Withdrawn EP0896622A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1365396P 1996-03-19 1996-03-19
US13653P 1996-03-19
PCT/US1997/004329 WO1997035010A1 (en) 1996-03-19 1997-03-19 Chemokine alpha 2

Publications (2)

Publication Number Publication Date
EP0896622A1 EP0896622A1 (en) 1999-02-17
EP0896622A4 true EP0896622A4 (en) 2004-11-03

Family

ID=21761043

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97916062A Withdrawn EP0896622A4 (en) 1996-03-19 1997-03-19 CHEMOKINE ALPHA 2

Country Status (9)

Country Link
US (3) US5910431A (enExample)
EP (1) EP0896622A4 (enExample)
JP (1) JP2000507101A (enExample)
KR (1) KR20000064765A (enExample)
CN (1) CN1217024A (enExample)
AU (1) AU733603B2 (enExample)
CA (1) CA2249997A1 (enExample)
NZ (1) NZ332318A (enExample)
WO (1) WO1997035010A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410268B1 (en) * 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
NZ332318A (en) * 1996-03-19 2000-10-27 Human Genome Sciences Inc Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
AU6132698A (en) * 1997-01-23 1998-08-18 Schering Corporation Mammalian chemokines; receptors; reagents; uses
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU1824499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Human cxc chemokine ((tim-1))
CA2320144A1 (en) * 1998-02-10 1999-08-12 Millennium Pharmaceuticals, Inc. Neokine protein and nucleic acid molecules and uses therefor
US6573095B1 (en) 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US20040258710A1 (en) * 1999-03-08 2004-12-23 Genentech, Inc. Novel polypeptides and nucleic acids encoding Bolekine
US20030096411A1 (en) * 1999-12-07 2003-05-22 George Michalopoulos Novel long-term three-dimensional tissue culture system
US6737270B1 (en) 1999-12-07 2004-05-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education Long-term three dimensional tissue culture system
CN1329090A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人自身免疫疾病相关蛋白10和编码这种多肽的多核苷酸
US20040151729A1 (en) * 2002-10-28 2004-08-05 George Michalopoulos Novel long-term three-dimensional culture system
US7648509B2 (en) 2003-03-10 2010-01-19 Ilion Medical Llc Sacroiliac joint immobilization
US20090024174A1 (en) * 2007-07-17 2009-01-22 Stark John G Bone screws and particular applications to sacroiliac joint fusion
US8740912B2 (en) 2008-02-27 2014-06-03 Ilion Medical Llc Tools for performing less invasive orthopedic joint procedures

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006196A1 (en) * 1990-09-28 1992-04-16 Cetus Oncology Corporation Gro genes, proteins, and uses thereof
EP0679716A1 (en) * 1993-11-12 1995-11-02 Kenichi Matsubara Gene signature

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897348A (en) * 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
US4897346A (en) * 1986-07-15 1990-01-30 Beckman Instruments, Inc. Stabilized liquid enzyme composition for glucose determination
US5212073A (en) * 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
CA2064558C (en) * 1989-09-25 2001-01-30 Ian B. Pragnell Method for inhibiting growth of stem cells
US5266302A (en) 1990-10-03 1993-11-30 Peyman Gholam A Method of performing angiography
US6001649A (en) * 1990-11-29 1999-12-14 Societe Anonyme: Elf Sanofi Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and their recombinant production
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US5346686A (en) * 1992-10-05 1994-09-13 Mallinckrodt Medical, Inc. Labelled interleukin-8 and medical uses thereof
EP0804486B1 (en) * 1992-11-27 2008-10-01 Laboratoires Serono SA Granulocyte chemotactic protein
JP2879303B2 (ja) * 1993-01-14 1999-04-05 佑 本庶 ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US5633149A (en) * 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US5605817A (en) * 1995-01-19 1997-02-25 Incyte Pharmaceuticals, Inc. DNA encoding chemokine expressed in fetal spleen
EP0811059A4 (en) * 1995-02-08 1998-04-01 Human Genome Sciences Inc HUMAN CHEMOKINE BETA-11 AND ALPHA-1
NZ332318A (en) 1996-03-19 2000-10-27 Human Genome Sciences Inc Chemokine alpha 2 and it's therapeutic and diagnostic use in treating illnesses
CA2248653C (en) 1996-05-01 2003-08-12 Genitope Corporation Vaccines for treatment of lymphoma and leukemia
US6222276B1 (en) * 1998-04-07 2001-04-24 International Business Machines Corporation Through-chip conductors for low inductance chip-to-chip integration and off-chip connections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006196A1 (en) * 1990-09-28 1992-04-16 Cetus Oncology Corporation Gro genes, proteins, and uses thereof
EP0679716A1 (en) * 1993-11-12 1995-11-02 Kenichi Matsubara Gene signature

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAO X ET AL: "Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 SEP 2000, vol. 165, no. 5, 1 September 2000 (2000-09-01), pages 2588 - 2595, XP001068275, ISSN: 0022-1767 *
See also references of WO9735010A1 *
TEKAMP-OLSON P ET AL: "Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 172, 27 August 1990 (1990-08-27), pages 911 - 919, XP002093659, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
AU2333097A (en) 1997-10-10
WO1997035010A8 (en) 2004-06-03
NZ332318A (en) 2000-10-27
US7122639B2 (en) 2006-10-17
JP2000507101A (ja) 2000-06-13
AU733603B2 (en) 2001-05-17
CN1217024A (zh) 1999-05-19
US6479633B1 (en) 2002-11-12
US20030082748A1 (en) 2003-05-01
EP0896622A1 (en) 1999-02-17
WO1997035010A1 (en) 1997-09-25
US5910431A (en) 1999-06-08
CA2249997A1 (en) 1997-09-25
KR20000064765A (ko) 2000-11-06

Similar Documents

Publication Publication Date Title
EP0896622A4 (en) CHEMOKINE ALPHA 2
MX9708537A (es) Quimiocina beta-8 quimiocina beta-1 y proteina-4 inflamatoria de los macrofagos, humanas.
DE69533627D1 (en) Humanes chemokin beta-13
ATE262345T1 (de) Menschliche chemokin-polypeptide
ATE290080T1 (de) Menschliches beta-9 chemokin
EP0814158A3 (en) Human C3a receptor variant; uses in diagnostics and therapeutics
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
EP0792370A4 (en) INTERLEUKIN-1 CONVERSION ENZYME-TYPE APOPTOSIS PROTEASE-3 AND 4 -g (b)
DE69637734D1 (de) Menschliches alpha-endokin
EP0837138A3 (en) Novel topoisomerase III
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP0812913A3 (en) HR-1 receptor, a receptor of the cytokine receptors family
EP0826774A3 (en) Staphylococcal Fab I enoyl-ACP reductase
EP0834568A3 (en) Novel saliva binding protein
EP0837136A3 (en) Novel topoisomerase I
EP0835938A3 (en) Topoisomerase I
EP0845535A3 (en) Leader peptidase (lep) from Streptococcus
MX9709090A (es) Quimiocina beta-11 humana y quimiocina alfa-1 humana.
WO2003085124A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
EP0839910A3 (en) Spo-rel, a Staphylococcus relA/spot homologue
EP0843011A3 (en) RsbU-1 derived from Staphylococcus
WO2003064589A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003050245A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP0838523A3 (en) RsbW-1 derived from Staphylococcus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040920

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/68 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 07K 16/24 B

Ipc: 7C 07K 14/52 B

Ipc: 7A 61K 38/19 B

Ipc: 7C 12N 15/19 A

17Q First examination report despatched

Effective date: 20050414

17Q First examination report despatched

Effective date: 20050414

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081202